Ȩ |  ÁÖ¿ä ÇÁ·Î±×·¥ |  ½ÉÆ÷Áö¾ö |  ÆÄÆ®³Ê¸µ Æ÷·³ |  ¿¬»ç ¾È³» |  ¼îÆ®ÄÚ½º |  ½ºÆù¼­ |  Æ÷½ºÅÍ Á¤º¸ |  °³ÃÖÁö |  ºê·Î¼Å(PDF) | ¹®ÀÇ |  Âü°¡½Åû |  (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç

Á¦1ȸ
Display of Difficult Targets
-¾î·Á¿î Ç¥Àû Ç¥½Ã ½ÉÆ÷Áö¾ö-

2¿ù 19ÀÏ¡­20ÀÏ

°áÁ¤±¸Á¶¸¦ ÀÔ¼öÇÒ ¼ö ÀÖ°Ô µÊÀ¸·Î½á À̿ ä³Î ¹× G´Ü¹éÁú°ø¿ª¼ö¿ëü(CPCR)¸¦ Æ÷ÇÔÇÑ ¸·´Ü¹éÁú¿¡ ´ëÇÑ ÀÌÇØ°¡ ±Þ¼ÓÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸·´Ü¹éÁú°ú ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÆÄÁö(Phage) ¹× È¿¸ð¸¦ Àû¿ë½ÃŰ´Â ¿¬±¸µµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÉÆ÷Áö¾öÀº ´Ü¹éÁúÀÇ ¼±ÅÃ, °ø°áÁ¤È­(co-crystallization), ¾Æ°í´Ï½ºÆ® °áÇÕ(agonist binding)°ú Ȱ¼ºÈ­, ¹ßÇö°ú Á¤Á¦¸¦ À§ÇÑ ¹æ¹ý µî¿¡ ÃÊÁ¡À» ¸ÂÃá °ÍÀ¸·Î, ÀÌ·¯ÇÑ ¹æ¹ýÀº ¾î·Á¿î Ç¥Àû¿¡ ´ëÇÑ ¾àÁ¦°³¹ß¿¡ µµ¿òÀÌ µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Who Should Attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Antibody Engineering, R&D, Lead Discovery, Diagnostics, Therapeutics, Biologics and Chemistry.

Topics will include, but are not limited to:

  • Insights from crystal structures of membrane proteins
  • Antibody selection against membrane proteins
  • Expression and purification of multi-pass proteins
  • Locking GPCR conformation with ligands or antibodies
  • Strategies for drug development
  • Evolution of ligands to membrane proteins

The deadline for submission is July 29, 2011.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Choose your language
English
Japan
Traditional Chinese
Simplified Chinese

À̺¥Æ® ͏°´õ
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö °ü·Ã ±¹Á¦ÄÁÆÛ·±½º

¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö °ü·Ã ±¹Á¦ÄÁÆÛ·±½º